BCL2 and lymphoma: Since antracyclines exert their cytotoxic activity at least in part by increasing ROS levels [52, 53] and determining oxidative DNA damage, lymphoma subsets displaying inherent tolerance to oxidative DNA damage through constitutive DDR activation and BCL-2 overexpression could be intrinsically resistant to current antracycline-based chemotherapeutic regimens.